tbuckley/cabot-search huggingface dataset:
1390P Impact of adding viagenpumatucel-L to nivolumab in non-small cell lung cancer (NSCLC) patients with low levels of tumour infiltrating lymphocytes
Authors: I. Bahce, S. Hashemi, M. Fransen, J. Veltman, L. McDermott, J. Hutchins, C. Caldwell, M. Argyres, B. Long, J. Wolf, E. Thunnissen
Journal: Annals of Oncology (2020)
264P Neutrophil-to-lymphocyte ratio as a prognostic factor for neoadjuvant chemotherapy for locally advanced breast cancer
Authors: B. Alshamsan, M.J. Aseafan, N. Fahmy, None A. badran, T. Elhassan, M.A. Elshenawy, A. Alsayed, K. Suleman, D.S. Ajarim, T. Al-Tweigeri
Journal: Annals of Oncology (2020)
730P Interim analysis of CASSIOPE: A real-world study of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy in Europe
Authors: G. Procopio, P. Hamberg, P. Bigot, C. Suarez, P. Barthélémy, J-C. Eymard, C. Masini, P. Gajate Borau, P. Dutailly, V. Perrot, M. Staehler
Journal: Annals of Oncology (2020)
1678P_PR The impact of COVID-19 pandemic on cancer care: A global collaborative study
Authors: A.R. Jazieh, H. Akbulut, G. Curigliano, A. Rogado, A.A. Alsharm, E. Razis, L.Y.I. Mula-Hussain, H. Errihani, A. Khattak, R.B. De Guzman, C.C. Mathias, M.O.F. Alkaiyat, H. Jradi, C.D. Rolfo
Journal: Annals of Oncology (2020)
Assessment of Data Sources That Support US Food and Drug Administration Medical Devices Safety Communications
Authors: Noam Tau, Daniel Shepshelovich
Journal: JAMA Internal Medicine (2020)

<h3>Importance</h3> Medical Device Safety Communications (MDSCs) are used by the US Food and Drug Administration (FDA) to convey important new safety information to patients and health care professionals. The sources of initial safety signals that trigger MDSCs have not been described previously. <h3>Objective</h3> To assess the sources of initial safety signals that trigger publication of MDSCs and the potential associations among MDSC data source, type of safety issue, and subsequent FDA action. <h3>Design, Setting, and Participants</h3> In this cross-sectional study, all MDSCs published on the FDA website between January 1, 2011, and December 31, 2019, were assessed. The MDSC characteristics, sources of initiating safety signals, regulatory approval or clearance pathways of the related medical devices, and subsequent FDA actions were collected from the FDA website. <h3>Main Outcomes and Measures</h3> The main outcome was the distribution of sources of initial safety signals that led to publication of MDSCs. Secondary aims included exploration of potential associations among safety signal sources (direct reporting vs other), type of safety issue (death vs other), and FDA action (withdrawal vs other). <h3>Results</h3> A total of 93 MDSCs were evaluated. Median time from device approval to MDSC posting was 10 years (interquartile range, 6-16 years). The most common data sources that triggered MDSCs were direct reports to the FDA through the Medical Device Reporting (MDR) program (44 of 93 [47%]) followed by regulator-initiated assessments (32 [34%]). Common safety issues included patient injury (25 [27%]), potential wrong diagnoses (19 [20%]), and death (18 [19%]). Frequent FDA action after MDSC posting included recommendation for increased vigilance and caution (47 [51%]), complete device withdrawal (12 [13%]), and warnings of specific lots or clinics (12 [13%]). There was a statistically significant correlation between direct reports of adverse events to the FDA through the MDR program and risk of death as a safety issue (14 of 44 [32%] for direct reporting vs 4 of 49 [8%] for any other data sources,<i>P</i> = .007). <h3>Conclusions and Relevance</h3> In this cross-sectional study, the most common source of initial safety signals that triggered MDSCs was direct reports of real-world adverse events to the FDA through the MDR program. The delayed detection of postmarketing adverse events highlights the importance of proactive identification of emerging device-related safety issues.
616MO Efficacy of BN-brachyury (BNVax) + bintrafusp alfa (BA) + N-803 in castration-resistant prostate cancer (CRPC): Results from a preliminary analysis of the Quick Efficacy Seeking Trial (QuEST1)
Authors: J.M. Redman, R.A. Madan, F. Karzai, M. Bilusic, L. Cordes, J. Marte, M. Manu, N. Williams, A. Hankin, C. Floudas, H. Abdul-Sater, M.E. Gatti-Mays, J. Strauss, S. Steinberg, W. Dahut, J. Schlom, J.L. Gulley
Journal: Annals of Oncology (2020)
1231P Significant impact of preoperative smoking period on postoperative prognosis in patients with surgically resected non-small cell lung cancer
Authors: S. Takamori, M. Shimokawa, T. Matsubara, T. Fujishita, K. Ito, M. Yamaguchi, R. Toyozawa, T. Seto, T. Okamoto
Journal: Annals of Oncology (2020)
Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020
Authors: Olivier Lortholary, Mario Fernandez-Ruiz, John W Baddley, Oriol Manuel, Xavier Mariette, Kevin L Winthrop
Journal: Annals of the Rheumatic Diseases (2020)

Biological therapies have improved the outcomes of several major inflammatory, autoimmune and also neoplastic disorders. Those directed towards cytokines or other soluble mediators, cell-surface molecules or receptors or various components of intracellular signalling pathways may be associated with the occurrence of infections whose diversity depends on the particular immune target. In this context and following a keynote lecture given by one of us at the European League Against Rheumatism meeting on June 2018, a multidisciplinary group of experts deeply involved in the use of targeted and biological therapies in rheumatoid and psoriatic arthritis decided to summarise their recent vision of the immunological basis and epidemiology of infections occurring during targeted and biological therapies, and provide useful indications for their management and prevention.
TSTA3 facilitates esophageal squamous cell carcinoma progression through regulating fucosylation of LAMP2 and ERBB2
Authors: Ling Zhang, Yingzhen Gao, Xiaojuan Zhang, Min Guo, Jie Yang, Heyang Cui, Pengzhou Kong, Xia Niu, Yanghui Bi, Jing Xu, Ting Yan, Yanchun Ma, Jian Yang, Yu Qian, Fang Wang, Hongyi Li, Feng Liu, Xiaolong Cheng, Yongping Cui
Journal: Theranostics (2020)

TSTA3 gene encodes an enzyme responsible for synthesis of GDP-L-fucose as the only donor in fucosylation. This study was designed to explore clinical value, function and underlying mechanism of TSTA3 in the development of esophageal squamous cell carcinoma (ESCC).
130P PTCH1 Genomic Alterations (GA) in human malignancies: A pangenomic study
Authors: J.S. Ross, E.S. Sokol, D.C. Pavlick, J-A. Vergilio, J.K. Killian, E. Williams, N.A. Danziger, J. Tse, S. Ramkissoon, E. Severson, A. Hemmerich, D. Duncan, R. Huang, R. Madison, A.B. Schrock, B. Alexander, J. Venstrom, P. Reddy, K. McGregor, J. Elvin
Journal: Annals of Oncology (2020)
582P Preclinical development of AT1412, a patient derived CD9 antibody that does not induce thrombosis for treatment of precursor B ALL
Authors: J. Villaudy, R. Schotte, G. de Jong, V. Neviani, W. Pos, S. Levie, E. Yasuda, M. Cercel, A. Szabó, C. Fatmawati, M. Kedde, S. Horbach, E.M.E. Verdegaal, P. van Helden, S.H. van der Burg, A. Rijneveld, P. Gros, H. Spits, M. Hazenberg, H. van Eenennaam
Journal: Annals of Oncology (2020)
1676MO Prevalence and clinical impact of asymptomatic or mildly symptomatic SARSCoV-2 infection among actively treated cancer patients during COVID-19 pandemic in Italy
Authors: A. Zambelli, V. Fotia, T. Bosetti, G. Negrini, A. di Croce, C. Moro, P.L. Poletti, A.C. Bettini, E. Arnoldi, C. Messina, B. Merelli, A.P. Callegaro, L. Chiudinelli, S. Mosconi, C. Tondini
Journal: Annals of Oncology (2020)
1646P Apatinib for treatment of inoperable metastatic or locally advanced chondrosarcoma: What we can learn about the biological behavior of chondrosarcoma from a multicenter study
Authors: L. Xie, J. Xu, X. Sun, K. Li, X. Li, F. He, J. Gu, Z. Lv, X. Tang, K. Sun, W. Guo
Journal: Annals of Oncology (2020)
Developing a Health Impact Model for Adult Lead Exposure and Cardiovascular Disease Mortality
Authors: Lauren Brown, Meghan Lynch, Anna Belova, Ryan Klein, Andrea Chiger
Journal: Environmental Health Perspectives (2020)

Background: Lead (Pb) is a highly toxic pollutant. Evidence suggests it is associated with cardiovascular disease (CVD)-related mortality. Objectives: We present a rigorous approach for identifying concentration–response functions that relate adult Pb exposures to CVD mortality to inform a health impact model (HIM). We then use the model in a proof-of-concept example. Methods: Building on previously conducted government literature reviews and a de novo supplemental literature review, we compiled and evaluated the available data on Pb and CVD mortality in humans. We applied a set of predefined selection criteria to identify studies that would be most useful in understanding the impact of Pb exposure on CVD mortality risk in adults. Once we identified the studies, we derived a HIM and used each study's concentration–response function in a proof-of-concept example. Results: Our literature search identified 15 studies for full-text review. Of those 15 studies, 4 fit our criteria for use in the HIM. Using population and CVD mortality rates for 40- to 80-y-olds in 2014, we estimated that 34,000–99,000 deaths have been avoided due to the lowering of blood Pb levels from 1999 to 2014. Based on these values we estimated that approximately 16%–46% of the decreased CVD-related death rate from 1999 to 2014 may be attributable to decreased blood Pb levels. Conclusion: Our results demonstrate that decreases in Pb exposure can result in large benefits for the adult population. We have provided a HIM that can be used in a variety of applications from burden-of-disease estimates to regulatory impact assessments and have demonstrated its sensitivity to the choice of concentration–response function. https://doi.org/10.1289/EHP6552
Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren’s syndrome with ectopic germinal centres and MALT lymphoma
Authors: Elena Pontarini, William James Murray-Brown, Cristina Croia, Davide Lucchesi, James Conway, Felice Rivellese, Liliane Fossati-Jimack, Elisa Astorri, Edoardo Prediletto, Elisa Corsiero, Francesca Romana Delvecchio, Rachel Coleby, Eva Gelbhardt, Aurora Bono, Chiara Baldini, Ilaria Puxeddu, Piero Ruscitti, Roberto Giacomelli, Francesca Barone, Benjamin Fisher, Simon J Bowman, Serena Colafrancesco, Roberta Priori, Nurhan Sutcliffe, Stephen Challacombe, Gianluca Carlesso, Anwar Tappuni, Costantino Pitzalis, Michele Bombardieri
Journal: Annals of the Rheumatic Diseases (2020)

Objectives To explore the relevance of T-follicular-helper (Tfh) and pathogenic peripheral-helper T-cells (Tph) in promoting ectopic lymphoid structures (ELS) and B-cell mucosa-associated lymphoid tissue (MALT) lymphomas (MALT-L) in Sjögren’s syndrome (SS) patients. Methods Salivary gland (SG) biopsies with matched peripheral blood were collected from four centres across the European Union. Transcriptomic (microarray and quantitative PCR) analysis, FACS T-cell immunophenotyping with intracellular cytokine detection, multicolor immune-fluorescence microscopy and in situ hybridisation were performed to characterise lesional and circulating Tfh and Tph-cells. SG-organ cultures were used to investigate functionally the blockade of T-cell costimulatory pathways on key proinflammatory cytokine production. Results Transcriptomic analysis in SG identified Tfh-signature, interleukin-21 (IL-21) and the inducible T-cell co-stimulator (ICOS) costimulatory pathway as the most upregulated genes in ELS+SS patients, with parotid MALT-L displaying a 400-folds increase in IL-21 mRNA. Peripheral CD4 + CXC-motif chemokine receptor 5 (CXCR5) + programmed cell death protein 1 (PD1) + ICOS + Tfh-like cells were significantly expanded in ELS+SS patients, were the main producers of IL-21, and closely correlated with circulating IgG and reduced complement C4. In the SG, lesional CD4 + CD45RO + ICOS + PD1 + cells selectively infiltrated ELS+ tissues and were aberrantly expanded in parotid MALT-L. In ELS+SG and MALT-L parotids, conventional CXCR5 + CD4 + PD1 + ICOS + Foxp3 - Tfh-cells and a uniquely expanded population of CXCR5 - CD4 + PD1 hi ICOS + Foxp3 - Tph-cells displayed frequent IL-21/interferon-γ double-production but poor IL-17 expression. Finally, ICOS blockade in ex vivo SG-organ cultures significantly reduced the production of IL-21 and inflammatory cytokines IL-6, IL-8 and tumour necrosis factor-α (TNF-α). Conclusions Overall, these findings highlight Tfh and Tph-cells, IL-21 and the ICOS costimulatory pathway as key pathogenic players in SS immunopathology and exploitable therapeutic targets in SS.
1496TiP Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma
Authors: F. Lordick, J. Chao, E. Buxò, H.W.M. van Laarhoven, C.M.R. Lima, S. Lorenzen, F. Dayyani, V. Heinemann, R. Greil, S. Stienen, K. Shitara
Journal: Annals of Oncology (2020)
448P Predictive factor of cardiotoxicity in fluoropyrimidine-treated colorectal cancer patients: Interim analysis of the prospective observational CHECKPOINT trial
Authors: G. Aimar, P. Lombardi, V. Quarà, M.C. Milanesio, V. Crespi, G. Farinea, R. Filippi, R. Ferraris, A. Bonzano, G. Cavalloni, C. Peraldo Neia, M. Aglietta, F. Leone, E. Fenocchio
Journal: Annals of Oncology (2020)
1452P Phase I study of apatinib plus POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC)
Authors: R. Lin, Z. Shen, F. Nanfeng, L. Hui, L. Jie, Y. Jiaqing, Z. Min
Journal: Annals of Oncology (2020)
Dynamic Whole-Body 18F-FDG PET for Minimizing Patient Motion Artifact
Authors: Tomohito Kaji, Kouji Osanai, Tomoaki Nakata, Nagara Tamaki
Journal: Clinical Nuclear Medicine (2020)

Abstract Recent PET/CT systems permit short acquisition with acceptable image quality. In addition, continuous-bed-motion mode is available for whole-body PET imaging with some PET cameras providing better uniformity and reproducibility throughout the field of view. We demonstrate a case with patient motion during the dynamic scan. Although the total summation of serial whole-body scan showed image artifact, the first 15 minutes’ summation of the serial scans provided high-quality images by eliminating the frames with motion. This acquisition mode seems to be particularly useful to perform for those who may likely to move during PET scan.
627P Real-world evidence (RWE) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ): Comparison with the randomized clinical study CARD
Authors: R. de Wit, S. Freedland, S. Oudard, G. Marinov, P. Capart, A. Combest, R. Peterson, A. Ozatilgan, A. Morgans
Journal: Annals of Oncology (2020)
Human recombinant soluble ACE2 in severe COVID-19
Authors: Alexander Zoufaly, Marko Poglitsch, Judith H Aberle, Wolfgang Hoepler, Tamara Seitz, Marianna Traugott, Alexander Grieb, Erich Pawelka, Hermann Laferl, Christoph Wenisch, Stephanie Neuhold, Doris Haider, Karin Stiasny, Andreas Bergthaler, Elisabeth Puchhammer-Stoeckl, Ali Mirazimi, Nuria Montserrat, Haibo Zhang, Arthur S Slutsky, Josef M Penninger
Journal: The Lancet Respiratory Medicine (2020)
1649P Outcomes of multidisciplinary treatment of fibromatosis – Retrospective analysis from a reference center
Authors: P. Sobczuk, I. Agnieszczak, W. Grycuk, A.M.M. Czarnecka, T. Switaj, H.M. Kosela Paterczyk, T. Morysiński, M. Zdzienicki, P. Rutkowski
Journal: Annals of Oncology (2020)
883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer
Authors: L.M. Randall, D.M. O'Malley, B.J. Monk, R.L. Coleman, R.E. O'Cearbhaill, S. Gaillard, S. Adams, F. Cappuccini, M. Huang, H.S. Chon, A.A. Secord, S. Arora, E. Keeton, D. Gupta, V. Samnotra, P. Konstantinopoulos
Journal: Annals of Oncology (2020)
584P Tepotinib exposure-response analyses of safety and efficacy in patients with solid tumours
Authors: P.K. Paik, W. Xiong, S.F. Hietala, J. Nyberg, O. Papasouliotis, R. Anziano, K. Berghoff, A. Johne, P. Girard, R. Strotmann
Journal: Annals of Oncology (2020)
LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
Authors: M. Tsuboi, Y-L. Wu, J. He, T. John, C. Grohe, M. Majem, J.W. Goldman, K. Laktionov, S-W. Kim, T. Kato, H.V. Vu, C. Akewanlop, C-J. Yu, F. de Marinis, M. Domine, F.A. Shepherd, C. Yan, A. Atasoy, R. Herbst
Journal: Annals of Oncology (2020)
Psychosocial adjustment to multiple sclerosis diagnosis: A meta-review of systematic reviews
Authors: Gogem Topcu, Holly Griffiths, Clare Bale, Emma Trigg, Sara Clarke, Kristy-Jane Potter, Jacqueline R. Mhizha-Murira, Avril Drummond, Nikos Evangelou, Deborah Fitzsimmons, Roshan das Nair
Journal: Clinical Psychology Review (2020)
833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer
Authors: D.M. O'Malley, D.L. Richardson, I.B. Vergote, L. Gilbert, C. Castro, D. Provencher, U.A. Matulonis, G. Mantia-Smaldone, L. Martin, P.A. Zweidler-Mckay, K.N. Moore
Journal: Annals of Oncology (2020)
1595P Connecting primary care with oncology through the implementation a cancer fast-track program: Reducing time from initial symptoms to diagnosis and initiation of treatment. A ten-year assessment
Authors: M.T.M. Martinez, B. Ortega, S. Simon, S. Moragon, J. Navarro, A. Sanmartin, A. Lluch, A. Cervantes, I. Chirivella Gonzalez
Journal: Annals of Oncology (2020)
914MO Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head &amp; neck squamous cell cancer (LA-HNSCC): Results of the GORTEC 2015-02 CisFRad randomized trial
Authors: C. Borel, X. Sun, A. Coutte, G. Bera, S. Zanetta, M. Alfonsi, G. Janoray, T. Chatellier, M. Garcia-Ramirez, E. Gherga, Y. Hammoud, N. Etienne-Selloum, A. Pechery, M.H. Girard-Calais, M. Velten, J-P. Pignon, M. Wanneveich, J. Bourhis
Journal: Annals of Oncology (2020)
1327P Benchmarking the efficacy and safety of pembrolizumab plus chemotherapy to pembrolizumab monotherapy: A consecutive analysis of NSCLC patients with high PD-L1 expression
Authors: H. Takumida, H. Horinouchi, K. Masuda, Y. Shinno, Y. Okuma, T. Yoshida, Y. Goto, N. Yamamoto, Y. Ohe
Journal: Annals of Oncology (2020)
588P Analysis and adherence to the ASCO recommendations for research biopsies and archival tissue requirements in clinical trials conducted at Institut Jules Bordet (IJB) from 2015 to 2019
Authors: L. Collet, N. Olympios, M. Paesmans, C. Jungels, N. Kotecki, A.H. Awada, P.G. Aftimos
Journal: Annals of Oncology (2020)
Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome
Authors: Michael A. Matthay, Katherine D. Wick
Journal: Journal of Clinical Investigation (2020)

Although corticosteroids dampen the dysregulated immune system and sometimes are prescribed as an adjunctive treatment for pneumonia, their effectiveness in the treatment of coronavirus disease 2019 (COVID-19) remains controversial. In this issue of the JCI, Liu and Zhang et al. evaluated corticosteroid treatment in more than 400 patients with severe COVID-19. The authors assessed subjects retrospectively for cardiac and liver injury, shock, ventilation, mortality, and viral clearance. Corticosteroids in severe COVID-19-related acute respiratory distress syndrome (ARDS) were associated with increased mortality and delayed viral clearance. Here, we consider how to reconcile the negative effects of corticosteroids revealed by Liu and Zhang et al. with the favorable effects (reduced mortality) that were described in the RECOVERY trial. We posit that treatment timing, dosage, and COVID-19 severity determine immune response and viral outcome. Patients with moderate-to-severe COVID-19 pneumonia are likely to benefit from moderate-dose corticosteroid treatment when administered relatively late in the disease course.
668P Clinical factors that are prognostic for survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223
Authors: E.M.M. Al-Ezzi, H.A. Alqaisi, M. Iafolla, S. Sridhar, A. Sacher, N. Fallah-Rad, D.M. Jiang, C. Catton, P. Warde, R. Hamilton, N. Fleshner, A. Zlotta, A. Hansen
Journal: Annals of Oncology (2020)
1325P Long-term survival and health-related quality of life in patients treated with nivolumab for advanced non-small cell lung cancer: A wide prospective French real-world study (EVIDENS)
Authors: F. Barlesi, A. Dixmier, D. Debieuvre, C. Raspaud, J.B. Auliac, N. Benoit, P. Bombaron, D. Moro-Sibilot, C. Audigier-Valette, B. Asselain, J. Dumanoir, F-E. Cotte, V. Allan, N. Ozan, C.Y. Calvet, D. Reynaud, M. Pérol
Journal: Annals of Oncology (2020)
1449P Hospital volume and beyond first-line palliative systemic treatment administration in metastatic esophagogastric adenocarcinoma: A population-based study
Authors: W.P.M. Dijksterhuis, R.H. Verhoeven, M. Pape, M. Slingerland, N. Haj Mohammad, None J. de vos-Geelen, L.V. Beerepoot, T. Van Voorthuizen, G-J. Creemers, V.E.P.P. Lemmens, M.G.H. van Oijen, H.W.M. van Laarhoven
Journal: Annals of Oncology (2020)
1412TiP Mobocertinib (TAK-788) as first-line treatment vs platinum-based chemotherapy (CT) for NSCLC with EGFR exon 20 insertions (exon20ins)
Authors: P.A. Jänne, Y-L. Wu, T. Kato, B. Besse, S. Peters, D. Nguyen, D. Berg, J. Lin, Z. Feng, T. Mok
Journal: Annals of Oncology (2020)
Response to: ‘Correspondence on ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Fallon<i>et al</i>
Authors: Xenofon Baraliakos, Laure Gossec, Iain McInnes, Andreas Kerschbaumer, Maarten de Wit, Maxime Dougados, Jette Primdahl, Désirée van der Heijde, Josef S Smolen
Journal: Annals of the Rheumatic Diseases (2020)

We thank Fallon and Jones1 for their correspondence on the European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis (PsA) and their comments on the clarity of the specific recommendation regarding the use of Janus kinase inhibitors (JAKi) in the management of PsA,2 which was based on the associated systematic literature research (SLR).3

We appreciate the support of the authors to provide as much clarification to the wording of our recommendations as possible, since these are the currently most up-to-date literature for the current and future treatment of patients with PsA.

In their remarks, Fallon and Jones refer to recommendation 7 and especially the wording on the safety signals of tofacitinib …
1639P Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors
Authors: F. Morschhauser, P. McKay, G. Salles, S. Stacchiotti, G.K. Schwartz, H. Tilly, M.G. Zauderer, D.A. Fennell, R.L. Jones, P. Schöffski, T. Phillips, A. Chaidos, V. Villalobos, G. Demetri, G. Cote, L. Sierra, J. Yang, P. Slatcher, S. Agarwal, M. Gounder
Journal: Annals of Oncology (2020)
574P Updated results of phase I study of senaparib (IMP4297) in Australian patients with advanced solid tumours
Authors: P. de Souza, B. Gao, M. Voskoboynik, K. Wilkinson, A. Cooper, S-N. Hoon, D. Palmieri, S. Cai, Y.E. Tian, C-Y. Hsieh, N. Ma, C. Xu, Y. Chen, S. Yang, S. Zhang
Journal: Annals of Oncology (2020)
580P AT1412, a patient-derived CD9 antibody promotes tumour immune infiltration and induces tumour rejection
Authors: R. Schotte, J. Villaudy, M. Kedde, W. Pos, K. Wagner, D. Go, C. Fatmawati, G. Moiset, E. Yasuda, M. Cercel, E. Frankin, S. van Hal-van Veen, P. van Helden, E.M.E. Verdegaal, H. van Eenennaam, S.H. van der Burg, H. Spits
Journal: Annals of Oncology (2020)